Curis (CRIS) Stock Price, News & Analysis

Company Overview

Curis, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation.

Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma. As an investigational medicine, emavusertib has not been approved for commercial use.

Founded in 2000 and headquartered in Lexington, Massachusetts, Curis has historically advanced drug candidates through internal research and strategic collaborations. The company previously collaborated with Genentech on hedgehog-pathway inhibitors, contributing to the development of Erivedge (vismodegib), which was approved for certain patients with advanced basal cell carcinoma. Curis has also worked with Aurigene Discovery Technologies on the development of emavusertib and related oncology programs.

Key Stats

• Today's Range: $0.76 to $0.95
• 50-Day Range: $0.38 to $1.49
• 52-Week Range: $0.33 to $28.40
• Volume: 2.53 million shs
• Average Volume: 12.08 million shs
• Market Capitalization: $3.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.00
• Consensus Rating: Hold

Curis Stock Analysis - MarketRank™

Curis scored higher than 42% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Curis has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Curis has a consensus price target of $43.00, representing about 4,643.5% upside from its current price of $0.91.

Amount of Analyst Coverage

Curis has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Curis are expected to decrease in the coming year, from ($15.65) to ($57.10) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Curis is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Curis is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Curis has a P/B Ratio of 0.11. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.31% of the float of Curis has been sold short.

Short Interest Ratio / Days to Cover

Curis has a short interest ratio ("days to cover") of 1.95, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Curis has recently increased by 144.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Curis does not currently pay a dividend.

Dividend Growth

Curis does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.13

News Sentiment

Curis has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Curis this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for CRIS on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Curis insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.54% of the stock of Curis is held by insiders.

Percentage Held by Institutions

29.97% of the stock of Curis is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/08/2026
• Next Earnings (Estimated): 11/12/2026
• EGM 2026: 11/18/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CRIS
• CIK: 1108205
• Web: www.curis.com
• Phone: (617) 503-6500
• Fax: 617-503-6501
• Employees: 24
• Year Founded: 2000

Price Target and Rating

• Average Price Target for Curis: $43.00
• High Price Target: $43.00
• Low Price Target: $43.00
• Potential Upside/Downside: +4,643.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($14.22)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.58 million
• Net Margins: N/A
• Pretax Margin: -490.33%
• Return on Equity: -2,365.94%
• Return on Assets: -200.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.49
• Quick Ratio: 0.49

Sales & Book Value

• Annual Sales: $9.44 million
• Price / Sales: 0.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.45 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 4,100,000
• Free Float: 4,042,000
• Market Cap: $3.72 million
• Optionable: No Data
• Beta: 3.28